Pre-made Utomilumab benchmark antibody ( Whole mAb, anti-TNFRSF9/CD137 therapeutic antibody, Anti-ILA/4-1BB/CDw137 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Utomilumab biosimilar, Whole mAb, Anti-TNFRSF9/CD137 Antibody: Anti-ILA/4-1BB/CDw137 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Utomilumab is the proposed non-proprietary name for PF-05082566, an investigational immunotherapy and a fully human IgG2 agonist monoclonal antibody (mAb) that binds to the extracellular domain of human 4-1BB/CD137 with high affinity and specificity.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-606-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Utomilumab biosimilar, Whole mAb, Anti-TNFRSF9/CD137 Antibody: Anti-ILA/4-1BB/CDw137 therapeutic antibody
INN Name	Utomilumab
Target	CD137
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG2
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	6a3w:GH:DE:AB:JK/6mi2:DE:AB
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2016
Year Recommended	2017
Companies	Dana-Farber Cancer Institute;Immatics US;Kite Pharma;Kyowa Hakko Kirin;M. D. Anderson Cancer Center;Pfizer
Conditions Approved	na
Conditions Active	Breast cancer;Oropharyngeal cancer;Solid tumours;B-cell lymphoma;Diffuse large B cell lymphoma;Follicular lymphoma;Ovarian cancer
Conditions Discontinued	Non-Hodgkin's lymphoma;Colorectal cancer
Development Tech	MorphoSys HuCAL Phage Display